Arrayed Imaging Reflectometry (AIR™) is Adarza’s core innovation and is our product’s competitive advantage.
AIR is an optical method fundamentally different from competing technologies, focusing on the suppression of background noise rather than amplifying a small signal. Because of our unique approach to detection, AIR breaks through the limitations of other label-free technologies.
- Massive Multiplexing – detect hundreds of analytes in a single drop of fluid
- Robust – very low CVs in a variety of complex matrices
- Sensitive – femtomolar limits of quantitation
- Fast – thousands of samples and hundreds of analytes in weeks, not years
- Simple workflow – incubate, wash & dry, read array, review data
- Affordable – high plex means dramatically lower cost per data point
- Broad dynamic range – conserve sample, no dilution necessary
AIR technology was invented at the University of Rochester. One of the first publications on this label-free technique as a method for determining low abundance proteins in biological solutions appeared in 2006 [Anal. Chem., 2006, 78 (15), pp 5578–5583]. The basic method has been employed to concurrently determine the concentrations of multiple proteins in serum and lysate ranging from 100 ng/ml – <10pg/ml [Biosens Bioelectron. 2011; 26 (9): 3944–3948]. The platform has also been adapted to use antigens to detect antibodies to viruses [Talanta. 2011; 83 (3):1000-5.] and measure RNA-protein interactions [Anal. Chem., 2014, 86 (2), pp 1067–1075].
Adarza BioSystems® was spun out of the University of Rochester with the purpose of commercializing AIR. The company has demonstrated utility detecting cytokines in serum with ≤ 10 pg/mL Lower Limit of Quantitation (LLOQ), small molecules from biological samples and binding of small molecules to protein kinases.
The versatility of the AIR platform means that it can serve as a central tool for solving a broad range of important biological problems. The academic research group of Adarza co-founder and SAB Chair Dr. Benjamin Miller is exploring ways to leverage AIR with well-known researchers in virology, vaccine biology, and drug discovery. For example, University of Rochester researchers are developing multiplex influenza antigen AIR chips able to profile the immune response to flu viruses in human or animal serum. Of use in surveillance applications and for testing the efficacy of candidate vaccines, these chips provide robust serological profiles at a fraction of the cost and complexity of standard methods. Miller’s lab has also developed a real-time version of the AIR technology, as a way to monitor hundreds of drug-target interactions simultaneously. Adarza supports University efforts through the sale of chips and reader systems, and expects to launch their first commercially available antibody based cytokine arrays this year.